Zoetis

YTD

ALL

Trade Zoetis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ZTS

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. It operates through the United States and International geographical segments.

CEO

Kristin C. Peck

CEOKristin C. Peck

Employees

14,500

Employees14,500

Headquarters

Parsippany, New Jersey

HeadquartersParsippany, New Jersey

Founded

1952

Founded1952

Employees

14,500

Employees14,500

ZTS Key Statistics

Market cap

32.24B

Market cap32.24B

Price-Earnings ratio

12.74

Price-Earnings ratio12.74

Dividend yield

2.68%

Dividend yield2.68%

Average volume

5.83M

Average volume5.83M

High today

$77.65

High today$77.65

Low today

$75.53

Low today$75.53

Open price

$76.43

Open price$76.43

Volume

1.41M

Volume1.41M

52 Week high

$160.48

52 Week high$160.48

52 Week low

$71.47

52 Week low$71.47

Stock Snapshot

As of today, Zoetis(ZTS) shares are valued at $76.91. The company's market cap stands at 32.24B, with a P/E ratio of 12.74 and a dividend yield of 2.68%.

On 2026-07-27, Zoetis(ZTS) stock moved within a range of $75.53 to $77.65. With shares now at $76.91, the stock is trading +1.8% above its intraday low and -1.0% below the session's peak.

Trading volume for Zoetis(ZTS) stock has reached 1.41M, versus its average volume of 5.83M.

The stock's 52-week range extends from a low of $71.47 to a high of $160.48.

ZTS News

TipRanks 4h

Zoetis price target lowered to $85 from $99 at UBS

UBS lowered the firm’s price target on Zoetis (ZTS) to $85 from $99 and keeps a Neutral rating on the shares. Unlock powerful investing tools with TipRanks Pre...

Simply Wall St 2d

How Lenivia’s Long-Acting Canine OA Launch At Zoetis Has Changed Its Investment Story

Zoetis has recently launched Lenivia (izenivetmab injection) in Canada and EU member states, a long-acting monoclonal antibody that provides up to three months...

Simply Wall St 3d

Zoetis Launches New Pet Pain Treatments As Valuation Questions Return

Zoetis (ZTS) is back in focus after launching Portela for cats and Lenivia for dogs in Canada and the EU, extending its osteoarthritis pain portfolio with long...

Analyst ratings

52%

of 21 ratings

Buy

52.4%

Hold

47.6%

Sell

People also own

Based on the portfolios of people who own ZTS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.